POSEIDA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)

Published: 2021-10-13 08:18:04 ET PSTX

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

Effective October 11, 2021, the Board of Directors of Poseida Therapeutics, Inc. (the "Company") appointed Johanna Mylet, the Company's Senior Vice President, Finance, as the Company's Chief Financial Officer. In connection with the appointment, Ms. Mylet succeeded Mark Gergen as the Company's principal financial officer. Ms. Mylet's employment is governed by an employment offer letter, dated June 8, 2015, a copy of which was filed as Exhibit 10.10 to the Company's Registration Statement on Form S-1 (File No. 333-239321) and is eligible to participate in the Company's compensatory plans with respect to executive officers described in its prior filings with the Securities and Exchange Commission, including its Definitive Proxy Statement filed April 28, 2021.

--------------------------------------------------------------------------------